Current Genes Tested by the Silver PGx Oncology Microarray Panel
The Silver PGx Oncology Panel analyzes germline variants across critical pharmacogenes. This list reflects the current content of the panel and is subject to updates as new clinical evidence and consensus guidelines emerge. All genes evaluated possess established CPIC guidelines or recognized clinical utility in oncology pharmacogenomics.
Gene Categories
Chemotherapy Response and Toxicity:
Genes with direct, high-impact influence on systemic chemotherapy metabolism, dosing, and severe toxicity risk.
Supportive Care Medications:
Genes relevant to supportive medications, pain management, anticoagulation risk, and other agents commonly used in oncology patients.
Chemotherapy Response and Toxicity
| Gene | Primary Clinical Relevance | Notes |
|---|---|---|
| DPYD | Fluoropyrimidine metabolism (5-FU, capecitabine) | Critical for reducing severe toxicity risk |
| TPMT | Thiopurine metabolism (mercaptopurine, thioguanine) | Important in hematologic malignancies |
| NUDT15 | Thiopurine metabolism | Complements TPMT for improved safety |
| UGT1A1 | Irinotecan metabolism | Guides dosing to minimize severe neutropenia and diarrhea |
Supportive Care Medications
| Gene | Primary Clinical Relevance | Notes |
|---|---|---|
| CYP2B6 | Metabolism of certain supportive and chemotherapeutic agents | Influences response and tolerability |
| CYP2C9 | Metabolism of select supportive and anti-inflammatory agents | Relevant for pain management and other therapies |
| CYP2C19 | Metabolism of several supportive care medications | Affects dosing of antidepressants, PPIs, and related agents |
| CYP2D6 | Tamoxifen metabolism and multiple supportive medications | Affects efficacy in hormone receptor-positive breast cancer |
| CYP3A5 | Metabolism of selected agents including tacrolimus | Relevant in transplant and certain oncology contexts |
| G6PD | Glucose-6-phosphate dehydrogenase deficiency screening | Important for safety with certain supportive medications |
| Factor II | Prothrombin gene mutation | Thrombosis risk assessment |
| Factor V | Factor V Leiden | Thrombosis risk assessment |
Laboratory Platform & Interpretation Standards
Testing Infrastructure: The panel is executed utilizing the Applied Biosystems™ Axiom™ PangenomiX Plus Array on the high-throughput GeneTitan™ MC platform from Thermo Fisher Scientific.
Allele Coverage: Variant and allele coverage for each targeted gene strictly aligns with current CPIC recommendations and molecular pathology best practices.
Clinical Curation: Results are interpreted and reported in strict accordance with peer-reviewed CPIC guidelines and curated by the laboratory’s clinical advisory resources.
Notice: This registry reflects the specific genes evaluated as of the most recent laboratory panel validation. Silver Gene Laboratories continuously monitors emerging clinical data and guidelines; panel content is subject to modification as new pharmacogenomic evidence is established. For the most current variant lists or validation documentation, please contact our clinical operations team directly.